Welcome to our dedicated page for American Vanguard SEC filings (Ticker: AVD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
American Vanguard Corporation's SEC filings document the formal disclosures of a NYSE-listed specialty agriculture products company and its AMVAC Chemical Corporation operating subsidiary. Recent Form 8-K reports cover operating results, earnings-call materials, Regulation FD disclosures and material credit arrangements, including term-loan and revolving-credit amendments tied to the company's capital structure and working-capital needs.
Proxy and annual-meeting filings address board elections, director composition, auditor ratification, executive compensation and shareholder voting matters. The filings also identify the company's common stock, par value, exchange listing and governance actions related to board size and committee-level oversight.
American Vanguard Corp director Patrick E. Gottschalk reported an open-market purchase of 25,000 shares of Common Stock at $2.70 per share. After this transaction, his directly held position increased to 191,705 shares, signaling a larger personal stake in the company.
AMERICAN VANGUARD CORP director Patrick E. Gottschalk bought 40,000 shares of Common Stock in the open market across two days. He purchased 20,000 shares on May 12 at $2.92 per share and 20,000 shares on May 13 at $2.95 per share. Following these transactions, he directly holds 166,705 shares of AMERICAN VANGUARD CORP common stock.
American Vanguard Corporation reported improved but still negative results for the quarter ended March 31, 2026. Net sales rose 7% to $123,568, led by 17% growth in U.S. crop and 6% growth in U.S. Specialty, while International sales fell 7%.
Gross profit increased 27% to $38,417, lifting gross margin to 31% from 26%. Operating expenses grew 6% to $36,528, including $2,804 of transformation costs and $659 of asset impairments tied to restructuring the Los Angeles plant. Net loss narrowed to $4,145 (basic and diluted loss per share of $0.14) from $8,462.
The company refinanced its credit facility with two term loans totaling $285,000, raising total debt (net of discounts and costs) to $266,634 and pushing quarterly interest expense to $5,790 at a 10.9% average rate. New covenants require minimum cash balances and restrict dividends and share repurchases. Management highlights geopolitical risks from war in the Middle East that could pressure growers’ costs and demand.
American Vanguard Corporation is holding its 2026 Annual Meeting of Stockholders virtually on June 3, 2026, at 11:00 a.m. Pacific Time. Stockholders will vote on electing seven directors, ratifying Deloitte & Touche as auditor, setting the frequency of Say‑on‑Pay votes, and approving 2025 executive pay.
The record date is April 10, 2026, with 34,244,580 shares issued and 28,541,878 entitled to vote. The board highlights recent refreshment, a reduced seven‑member size tied to a new term loan, and a majority of independent directors. Executive pay is described as performance‑based, with 2025 bonuses at roughly one‑third of target after flat financial results and no new equity grants.
American Vanguard Corporation reports that three current directors, Scott Baskin, Emer Gunter and Carmen Tiu de Mino, have notified the Board that they will not stand for re-election at the 2026 annual meeting of stockholders. This follows a prior agreement tied to a First Lien Term Loan requiring the Board to shrink from nine to seven members and add one independent director within 90 days following March 13, 2026. The company states that the directors’ decisions are not due to any dispute or disagreement over operations, policies, practices or other matters.
The Vanguard Group amended its Schedule 13G reporting for American Vanguard Corp common stock, stating 0 shares beneficially owned (0%) as of the filing. The amendment attributes the change to an internal realignment on January 12, 2026 under SEC Release No. 34-39538, with subsidiaries reporting separately and pursuing the same investment strategies. The amendment is signed by Ashley Grim on March 26, 2026.
American Vanguard Corporation, through subsidiary AMVAC Chemical, entered into new first- and second-lien term loans totaling $285 million. A senior secured First Lien Term Loan provides $225 million for five years, initially bearing interest at a SOFR-based rate plus 8.25%, with a 1% in‑kind leverage fee when consolidated leverage exceeds 5.00:1.00. A Second Lien Term Loan adds $60 million at SOFR plus 2.00%, subject to a 3.00% SOFR floor. The proceeds refinance and retire all loans under the prior credit agreement and fund about $68.5 million for general corporate and working capital uses. The loans mature on March 13, 2031 and include liquidity and leverage covenants, quarterly principal amortization, and an intercreditor agreement giving first‑lien lenders priority on shared collateral. Governance covenants require adding independent directors, reducing the parent board to seven members, and securing the independent director’s approval for any voluntary bankruptcy of direct domestic subsidiaries.
American Vanguard Corporation reported a challenging but improving 2025, with net sales of $515.1 million, down 6%, and a net loss of $49.9 million, substantially narrower than the prior year’s loss. Gross margin improved to 29% from 22% as cost controls and manufacturing efficiencies took hold.
The company generated Adjusted EBITDA of $39.2 million, roughly flat with 2024, and is targeting Adjusted EBITDA of $44–$48 million on 2026 sales of $530–$550 million. Management is rationalizing its Los Angeles manufacturing facility, expecting at least $4 million of annual savings, and relocating its headquarters from Newport Beach to Irvine for about $0.5 million in yearly savings.
American Vanguard replaced its revolving credit facility with two term loans, which it says extend maturities and strengthen liquidity, though at a higher average interest cost. The company also fully remediated all material weaknesses identified in the 2024 audit and continues to emphasize new product launches and digital initiatives to drive medium-term growth.
American Vanguard Corporation reported 2025 net sales of $515.1 million and a net loss of $49.9 million, a substantial improvement from a $126.3 million loss in 2024. Gross margin rose to 29% from 22% as cost of sales fell 14%, helped by lower inventory write-downs and better procurement.
U.S. net sales were roughly flat at $311.7 million, with weaker crop sales offset by stronger non‑crop revenue, including $11.25 million from a technology licensing deal. International sales declined 14% to $203.4 million, mainly from drought in Australia and high channel inventories in Mexico.
Operating expenses fell 21% to $175.9 million, driven by lower transformation spending, reduced research and regulatory costs, and smaller impairment charges, partly offset by $9.7 million in product liability claims. Average debt remained high at $194.7 million, with net interest expense of $18.5 million at an effective 9.5% rate, and year‑end senior credit facility borrowings of $174.0 million.
American Vanguard Corp received an amended Schedule 13G showing that Topline Capital Management, Topline Capital Partners and Collin McBirney now report beneficial ownership of 0 shares, or 0% of the common stock, as of 12/31/2025.
The filers state they previously acquired and held the securities in the ordinary course of business and not to change or influence control of American Vanguard, other than activities solely in connection with a director nomination process.